Tyrrell, C J <br/><br/>
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.  [electronic resource] 

 -  European urology  1998 
 - 39-53 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Controlled Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0302-2838 
<br/><br/><label>Standard No.: </label>10.1159/000019526  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acid Phosphatase--blood<br/>Androgen Antagonists--pharmacokinetics<br/>Anilides--administration & dosage<br/>Antineoplastic Agents--pharmacokinetics<br/>Dose-Response Relationship, Drug<br/>Estradiol--blood<br/>Follicle Stimulating Hormone--blood<br/>Humans<br/>Liver Function Tests<br/>Luteinizing Hormone--blood<br/>Male<br/>Neoplasm Invasiveness--pathology<br/>Neoplasm Metastasis<br/>Neoplasm Staging<br/>Nitriles<br/>Prostate-Specific Antigen--blood<br/>Prostatic Neoplasms--blood<br/>Testosterone--blood<br/>Tosyl Compounds